ALA Share Price Performance
AU$0.06
-0.02 (-25.00%)
Price AU$0.06
Share Pricen/a
Arovella Therapeutics Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
ALA Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Arovella Therapeutics Limited Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.0057
- 100.00%
- -197.72%
- 0%
About ALA
- Founded
- 1999
- Employees
- n/a
- CEO
- WebsiteView website
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
